Arecor IPO raises £20m

Arecor Therapeutics plc completed their IPO with shares admitted to trading on AIM on 3rd June. Panmure Gordon acted as Nomad, Sole Broker and Sole Bookrunner on the transaction to raise £20m.

Arecor Therapeutics plc is globally focused biopharmaceutical company, that is targeting improving patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products,

Sarah Howell, Chief Executive Officer of Arecor, said: “This IPO will allow us to continue to grow the business through the development of our own proprietary diabetes and specialty hospital products whilst creating further value through our technology licensing partnerships. We were delighted by the support and interest we received during this transaction which is testament to the potential of our innovative proprietary formulation technology platform, Arestat™.”